Oncology Institute furnishes new investor presentation

The Oncology Institute, Inc. filed a current report to make investors aware of a new investor presentation.

(Moderate)

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

The Oncology Institute, Inc. filed a current report to make investors aware of a new investor presentation. The company plans to use this presentation in meetings with investors to explain its business and outlook. The presentation is included as Exhibit 99.1 and is dated March 13, 2026.

The material in the investor presentation is being furnished under Regulation FD, which means it is provided for information purposes and is not treated as filed financial statements. The company’s common stock trades on the Nasdaq Stock Market under the symbol TOI, and its redeemable warrants trade under the symbol TOIIW.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did The Oncology Institute, Inc. disclose in this 8-K filing?

The Oncology Institute, Inc. disclosed that it prepared a new investor presentation for use in meetings with investors. This presentation is furnished as Exhibit 99.1 and is dated March 13, 2026, under Regulation FD disclosure rules.

How is the investor presentation by The Oncology Institute, Inc. treated under SEC rules?

The investor presentation is furnished, not filed, under Regulation FD. This means it is not subject to Section 18 liability and is not automatically incorporated into other Securities Act or Exchange Act filings by The Oncology Institute, Inc.

Where can investors find The Oncology Institute, Inc.’s investor presentation from March 13, 2026?

Investors can find the March 13, 2026 investor presentation as Exhibit 99.1 attached to the company’s current report. The exhibit is part of the Inline XBRL document associated with this 8-K filing.

What stock exchange lists The Oncology Institute, Inc. common stock and warrants?

The Oncology Institute, Inc. common stock is listed on The Nasdaq Stock Market under the symbol TOI. Its redeemable warrants, each exercisable for one common share at $11.50 per share, trade under the symbol TOIIW on Nasdaq.

Who signed The Oncology Institute, Inc.’s March 13, 2026 current report?

The current report was signed on behalf of The Oncology Institute, Inc. by Robert Carter, the company’s Chief Financial Officer. The signature is dated March 13, 2026, confirming the company’s authorization of the disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/13/2026 - 05:16 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

Form 8-K

__________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 13, 2026

___________________________________

THE ONCOLOGY INSTITUTE, INC.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware		001-39248		84-3562323
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

18000 Studebaker Road, Suite 800, Cerritos, CA		90703
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (562) 735-3226

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001	TOI	The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share	TOIIW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐.

Item 7.01. Regulation FD Disclosure.

The Oncology Institute, Inc. (the “Company”) has prepared an investor presentation (the “Investor Presentation”) to use in meetings with investors. A copy of the Investor Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

(d)

The following exhibits are being filed herewith:

Exhibit		Description
99.1		Investor Presentation, dated March 13, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.